Lupin faces contrasting analyst recommendations with Motilal Oswal maintaining a Neutral rating and a target price of ₹2,500 (August 08, 2026), while ICICI Securities has downgraded to Reduce with a lower target of ₹2,200 (August 09, 2026). According to Motilal Oswal's analysis, the pharmaceutical company delivered better-than-expected financial performance in Q1FY27, with the stock showing mixed signals across different business segments. ICICI Securities' downgrade reflects concerns about competitive pressures and margin sustainability in key markets.
As reported by Motilal Oswal, Lupin delivered a 5% beat on revenue and a 15% beat on EBITDA for the first quarter of FY27. The revenue outperformance was driven by strong performance in other developed markets and emerging markets segments, which surprised considerably on the revenue front. The domestic formulation and US business segments were marginally better than expectations, while the US business continues to maintain strong fundamentals with stable performance from niche opportunities and volume growth in base business. ICICI Securities notes that Q1FY27 exceeded expectations, led by exclusivities in the US (+29.8%) and robust growth in emerging (+51.7%) and other developed markets (+48.3%).
According to ICICI Securities research, around 50% of Lupin's US revenue is at risk of attracting competition, with Tolvaptan getting impacted in FY27 and Mirabegron and gSpiriva in FY28. Competition intensity in select exclusive products is expected to rise, posing significant challenges to the company's US market position. Despite these headwinds, management has maintained single-digit revenue growth and ~25% EBITDA margin guidance for FY27, indicating confidence in the company's ability to navigate competitive pressures.
According to Motilal Oswal's research, the brokerage has reduced earnings estimates by 6% for FY27 to account for increased depreciation and higher tax rates. Despite the earnings revision, the target price of ₹2,500 is maintained using a valuation multiple of 22x 12-month forward earnings. ICICI Securities has cut FY27/28E EPS by 2-5% to factor in lower margins, justifying their downgrade to Reduce. The PAT beat was lower than expected due to higher depreciation and tax rate impacts, which offset the positive revenue and EBITDA performance across different analyst assessments.
